High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment
Bai, M. C.
SourceLeukemia and Lymphoma
Google Scholar check
MetadataShow full item record
Gene copy number and protein expression of topoisomerase IIα were correlated to benefit from anthracyclines in various tumors. A retrospective series of 69 patients with DLBCL managed with CHOP chemotherapy were studied for immunohistochemical TopoIIα expression and numerical gene abnormalities by fluorescent in situ hybridization (FISH). The results were analyzed in relation to the expression of cell cycle proteins (Ki67, p53, HDM2, p21, p14, pRb, p16, and cyclins A, B1, D1, D2, D3, and E) and BCL6/CD10/MUM1/CD138 B-cell differentiation immunophenotype and outcome. High levels of TopoIIα protein were found in 91 of DLBCL cases. No evidence of TopoIIα gene amplification or deletion was found. The TopoIIα expression showed significant positive correlations with the proliferation index Ki67 (p0.002), cell cycle proteins pRb and cyclin D2 (p0.018 and p0.028, respectively), and the germinal center proteins bcl6 and CD10 (p0.010 and p<0.0001, respectively). TopoIIα expression was significantly higher in germinal center B-cell like (GCB) DLBCL than in non-germinal center B-cell like (non-GCB) DLBCL (p0.048). TopoIIα protein was significantly associated with response to chemotherapy (χ2, p0.024), but not with relapse-free or overall survival (p0.5). On multivariate analysis, only stage of disease retained independent prognostic significance (HR 0.33 for early stage, p0.008). Although TopoIIa gene copy number abnormalities were not found in DLBCL, high levels of protein expression are associated with GCB-cell differentiation immunophenotype, high proliferation, and response to treatment. © 2010 Informa Healthcare USA, Inc.
Showing items related by title, author, creator and subject.
Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas Bai, M. C.; Vlachonikolis, J.; Agnantis, Niki J.; Tsanou, E.; Dimou, S.; Nikolaides, C.; Stefanaki, S. V.; Pavlidis, Nicholas; Kanavaros, P. (2001)The expression of the cyclin-dependent kinase inhibitor (CDKI) p27 protein was investigated in relation to (1) the expression of the cell cycle regulators p53, Rb and p16 and (2) the proliferation profile as determined by ...
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): A study of 100 CUP cases Golfinopoulos, Vassilis; Pentheroudakis, George; Goussia, Anna; Siozopoulou, V.; Bobos, M.; Krikelis, D.; Cervantes, A.; Ciuleanu, T.; Marselos, M.; Fountzilas, George; Malamou-Mitsi, Vassiliki D.; Pavlidis, Nicholas (2012)Background: Hypothesising that cancer of unknown primary (CUP) may harbour unique characteristics, we present a translational study of the immunohistochemical expression and clinical correlation of key PTEN/AKT pathway ...